Metabolism inhibitors for cancer treatment

Our Team

We assembled a team with deep expertise in oncology venture development to execute on our mission to exploit metabolic vulnerabilities in oncogene addicted cancers. The team previously navigated the development of multiple oncology drugs from preclinical stage to the market. In particular, the team successfully developed the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib for mantle cell lymphoma and chronic lymphocytic leukemia.